In the last trading session, 2.08 million Pyxis Oncology Inc (NASDAQ:PYXS) shares changed hands as the company’s beta touched 1.00. With the company’s per share price at $2.00 changed hands at -$0.01 or -0.50% during last session, the market valuation stood at $130.63M. PYXS’s last price was a discount, traded about -242.5% off its 52-week high of $6.85. The share price had its 52-week low at $1.56, which suggests the last value was 22.0% up since then. When we look at Pyxis Oncology Inc’s average trading volume, we note the 10-day average is 3.61 million shares, with the 3-month average coming to 1.04 million.
Analysts gave the Pyxis Oncology Inc (PYXS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PYXS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
Instantly PYXS was in red as seen at the end of in last trading. With action 5.26%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 11.11%, with the 5-day performance at 5.26% in the green. However, in the 30-day time frame, Pyxis Oncology Inc (NASDAQ:PYXS) is -43.82% down. Looking at the short shares, we see there were 5.84 million shares sold at short interest cover period of 8.24 days.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 80.0% from its current market value. According to analyst projections, PYXS’s forecast low is 7 with 10 as the target high. To hit the forecast high, the stock’s price needs a -400.0% plunge from its current level, while the stock would need to soar -250.0% for it to hit the projected low.
Pyxis Oncology Inc (PYXS) estimates and forecasts
Data shows that the Pyxis Oncology Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -46.81% over the past 6 months, a 44.32% in annual growth rate that is considerably higher than the industry average of 16.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -118.72%. The 2024 estimates are for Pyxis Oncology Inc earnings to increase by 41.24%, but the outlook for the next 5-year period is at 34.60% per year.
PYXS Dividends
Pyxis Oncology Inc is expected to release its next quarterly earnings report in January.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 24.54% of Pyxis Oncology Inc shares while 54.52% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 72.25%. There are 54.52% institutions holding the Pyxis Oncology Inc stock share, with DEEP TRACK CAPITAL, LP the top institutional holder. As of 2024-06-30, the company held 8.1578% of the shares, roughly 4.18 million PYXS shares worth $13.85 million.
LAURION CAPITAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 7.5282% or 3.86 million shares worth $12.78 million as of 2024-06-30.
